‘Great pride to every Indian’, says NIV-ICMR as Covaxin phase3 data announced

The National Institute of Virology-ICMR Director has praised Bharat Biotech for creating Covid vaccine — Covaxin. The Hyderabad-based firm on Friday introduced the security and efficacy evaluation information from phase-3 scientific trials of Covaxin, which is developed in partnership with ICMR and NIV.

Efficacy evaluation demonstrated Covaxin to be 77.8 per cent efficient towards symptomatic Covid and 93.4 per cent efficient towards extreme symptomatic virus.

Speaking on the outcomes, Professor (Dr) Priya Abraham, Director National Institute of Virology ICMR mentioned: “The overall efficacy of 77.8% following the phase III clinical trial of COVAXIN is wonderful news.”

“ICMR-NIV and BBIL (Bharat Biotech) have had very fruitful interactions during this exhilarating journey. Sera from COVAXIN recipients have also been evaluated against viral variants detected in India i.e., the Alpha, Beta, Zeta, Kappa and Delta. The making of this vaccine entirely on Indian soil is a matter of great pride to every Indian,” Abraham mentioned.


Covaxin has now obtained emergency use authorizations in 16 nations together with, Brazil, India, Philippines, Iran, Mexico, and many others. with EUA’s in course of in 50 nations worldwide. The firm is in discussions with WHO to acquire emergency Use Listing for Covaxin. The product has been exported to a number of nations with further requests for provides being obtained.

Source link